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Macroporous monolithic composites with embedded divinylbenzene-styrene (DVB-ST) polymeric particles were
prepared by cryogelation techniques using poly(vinyl alcohol) or agarose solutions. Scanning electron microscopy
images showed multiple interconnected pores with an average diameter in the range of 4 to 180 μm and quite
homogeneous distribution of DVB-ST particles in the composites. Biocompatibility of the composites was assessed
by estimation of the C5a fragment of complement in the blood serum and concentration of fibrinogen in the
blood plasma which contacted the composites. A time-dependent generation of C5a fragment indicated weak
activation of the complement system. At the same time, the difference in fibrinogen concentration, one of the
most important proteins in the coagulation system of the blood, between the pristine blood plasma and the
plasma, circulated through the monolithic columns, was insignificant.
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FibrinogenBackground
Macroporous monolithic materials produced from
hydrophilic polymers by cryogelation techniques find
more and more applications in biomedical science and
technology. The areas for material applications are separ-
ation and purification of proteins (Dainiak et al. 2004),
bioaffinity screening techniques (Hanora et al. 2005), syn-
thesis of adsorbents for water purification (Le Noir et al.
2007), or development of tissue-engineering scaffolds
(Bolgen et al. 2007) including those used for wound
healing (Dainiak et al. 2010). Cryogelation is a process of
gel formation, which takes place in a semi-frozen state.
Under such condition, the gel forms in narrow unfrozen
zones with high concentrations of reagents. At the same
time, the crystals of frozen aqueous medium act as
porogens and form large interconnected pores appearing
after defrosting (Kirsebom et al. 2009). The cryogelation
techniques allow preparation of elastic mechanically stable* Correspondence: blg_lida@yahoo.com
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in any medium, provided the original work is pmonolithic matrices easily permeable to aqueous solutions
of proteins and suspensions of cells. The monolithic gels
exhibit multiple interconnected pores of 1 to 100 μm in
diameter, which can be controlled by changing the condi-
tions of synthesis (Kirsebom et al. 2009; Plieva et al. 2007).
Various types of monolithic porous polymer structures,
MPPS™, produced by cryogelation of hydrophilic poly-
mers were developed by Protista (www.protista.se). An at-
tractive feature of the cryogelation technique is the
possibility to embed suspended dispersed materials such
as polymeric microparticles into the monoliths, which al-
lows for increased absorption capacity and targeting the
adsorbents against selected compounds (Ivanov et al.
2012; Koc et al. 2011; Özgür et al. 2011). Recently, poly-
styrene microparticles were shown to be effective adsor-
bents for liver toxins such as bilirubin, bile acid, and
aromatic amino acids (Weber et al. 2008). In terms of this
concept, the composite cryogels with embedded adsorp-
tive microparticles can be considered as promising mate-
rials for extracorporeal blood purification and removal of
liver toxins, pro-inflammatory factors, xenobiotics, oris an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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extracorporeal blood purification, the removal of toxic
metabolites from human or animal plasma is challenging
in view of production of cell growth media. In particular,
removal of toxic metabolites related to liver failure or pro-
inflammatory cytokine tumor necrosis factor is a need for
the studies performed with cultured hepatocytes (Saich
et al. 2007; Jones and Czaja 1998). The above production
processes and research applications are required for ad-
sorbent devices with low resistance to the flow of plasma
combined with effective adsorption of various toxins. The
permeable monolithic composites suggest an adequate
type of the adsorbent.
However, materials that are supposed to be in contact
with human organisms or blood plasma must be biocom-
patible, in particular, concerning their interaction with clot-
ting and complement systems of the blood (Kirkpatrick
et al. 1998). Both agarose and poly(vinyl alcohol) (PVA)
were earlier used to synthesize biomaterials (Varoni et al.
2012; Paradossi et al. 2003) Correspondingly, the aim of
the present study was to assess the possibility of biomed-
ical applications of the composite cryogels based on PVA
or agarose with embedded divinylbenzene-styrene (DVB-
ST) polymeric microparticles. To achieve this, the estima-
tion of the C5a component of complement and fibrinogen
in the human blood serum or plasma during their contact
with the above composite materials has been performed.
In view of the different chemical structures of the chosen
polymers and, consequently, different methods of cryo-
gelation, the difference in their microstructure anda. x150
b. x1200
Figure 1 SEM micrographs of slices of the particle-free monolithic cry
5% PVA solution.interaction with embedded polymeric microparticles can
be expected. Thus, another aim of the study was the
characterization of the microstructure of monolithic
composites.
Results and discussion
Microstructure of the composite and non-composite
monoliths
Micrograph comparison of particle-free agarose and PVA
slices, observed by scanning electron microscopy (SEM)
at low magnification (Figure 1), has shown that both types
of the cryogel monoliths had quite similar structures with
evenly distributed interconnected pores, with an average
pore size within the range 4 to 100 μm. However, at higher
magnification, the difference between the structure of
agarose and PVA gels could be observed. The PVA cryogel
has porous thick walls of about 10 to 30 μm (Figure 1d) in
contrast with the smooth thin (approximately 2 μm) walls
of the agarose gel. No visible pores in the walls of the aga-
rose matrix could be seen on the SEM micrographs
(Figure 1b). In theory, the different porosities of the
particle-free monoliths gels may result in different adsorp-
tion characteristics due to an increase in the total binding
surface area of the PVA monoliths with porous walls.
Both PVA- and agarose-based composites that consist of
DVB-ST polymeric particles connected by sheets and brid-
ges of the cryogelated polymers and exhibited large cavities
(up to 180 μm in diameter) are detectable throughout the
materials, whereas the mean pore size was 30 μm (Figure 2).
Some pores of the larger sized particles observed in thec. x150
d. x1200
ogels. They are prepared from (a, b) 3% agarose solution and (c, d)
a. x35 b. x35
Figure 2 SEM micrographs of slices of cryogel monoliths. At (a) 3% agarose and (b) 5% PVA with embedded DVB-ST polymeric particles.
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which resulted in 96% shrinkage of the particle-free agarose
and PVA, but not of the composites. Resistance of the
composites to shrinkage could be explained by the higher
mechanical stability provided by the particles.
Important features of the cryogel composites were high
density and homogeneous distribution of the embedded
particles in the polymer matrices. There was no big differ-
ence between the content of DVB-ST beads in the slices
obtained from the top (Figure 3a,c) and the bottom
(Figure 3b,d) of the agarose- and PVA-based composites.
It is worth noting that some parts of the DVB-ST poly-
meric particles were tightly embedded or even wrapped in
the cryogel matrix, whereas some other parts remained
free (Figure 3).
The presence of relatively narrow (4 μm in diameter)
pores in cryogel monoliths, as well as the high packing
density of DVB-ST polymeric particles, could be a res-
tricting factor for the passage of whole blood through
the composites. Some types of leukocytes with sizes of
10 to 21 μm might be stuck in the narrow pores. How-
ever, this does not preclude an application possibility of
these materials for purification of blood plasma, which
could be easily percolated through the monoliths by
peristaltic pumping. According to the obtained data, the
throughput capacity of the cryogel composites under a
pressure of 1 kPa was 0.5 mL/min.Adsorption of fibrinogen
For biocompatibility of new biomaterials, determination
of fibrinogen as well as some fragments of comple-
ment called ‘split products’ in the contacting blood is a
mandatory test according to the ISO regulatory docu-
ments (ENSAI 2009). Fibrinogen is one of the most
important proteins in the coagulation process. Absorp-
tion of the fibrinogen homodimer on the surface of any
material in contact with blood can mediate the forma-
tion of platelet aggregates, further leading to thrombosis
(Vogler and Siedlecki 2009; Beugeling 1979). Concentra-
tion of the fibrinogen in blood plasma samples beforeand after their passage through the monoliths, both
noncomposite and composite, is illustrated in Figure 4.
Judged by the obtained data, there was no statistically sig-
nificant depletion of fibrinogen from the blood plasma
which contacted the composites in comparison with the
plasma passed through the pumping system without mono-
liths. The low adsorption of fibrinogen on the monoliths
may be explained by two independent reasons. The first
one is that this protein is known to be rapidly (within 1 to
2 min) adsorbed by a number of artificial materials, which
then gradually release the protein in the plasma (Brash
et al. 1988). This phenomenon is due to the displacement
of fibrinogen by the other plasma proteins, and it is called
the Vroman effect (Brash et al. 1988; Vroman et al. 1980).
The equilibrium amount of fibrinogen adsorbed from the
blood plasma on nonporous polystyrene was found to be as
low as 250 ng/cm2 (Tsai et al. 1999). This could be a reason
why the fibrinogen concentration in the samples of plasma
percolated through the monoliths for 30 min was almost
the same as that found in the native plasma. The second
reason is that the embedded DVB-ST microparticles might
have too little fraction of pores accessible for the adsorption
of fibrinogen, a relatively large protein with a molecular
weight of 340 kDa, and a hydrodynamic radius of 12.7 nm
determined at physiological conditions (Wasilewska et al.
2009). The latter hypothesis can be checked by the follow-
ing calculation. The outer specific surface area of 75-μm
DVB-ST beads of known bulk density (0.28 g/cm3) can be
estimated as ca. 0.14 m2/g. Note that the total specific sur-
face area of the beads (SBET = 641 m
2/g) is 4,500 times lar-
ger due to the inner porosity of the beads (Table 1). Thus,
the DVB-ST beads contained in a composite cryogel
monolith (500 mg, see the ‘Methods’ section) might have a
maximum outer surface area of 0.07 m2 available for this
protein adsorption. One can evaluate the corresponding
equilibrium amount of fibrinogen adsorbed on the outer
surface as ca. 180 μg/monolithic gel. Under the conditions
of the experiment and at ±0.3 mg/mL standard deviation of
fibrinogen concentration measurements (see Figure 4), the
mentioned adsorbed amount would be within the limits of
the experimental error (±1 mg fibrinogen/gel). Since there
a. x150 c. x150
b. x150 d. x150
Figure 3 SEM micrographs of slices of 3% agarose and 5% PVA cryogel monoliths. (a, b) 3% agarose and (c, d) 5% PVA cryogel monoliths
with embedded DVB-ST polymeric particles.
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fibrinogen concentrations in the native and the percolated
plasma samples (Figure 4), neither the pores of the DVB-
ST beads nor the cryogelated polymer structures (PVA or
agarose) (see Table 1) could provide essentially more bind-
ing sites for fibrinogen than the outer surface of the beads.
The composite monoliths adsorbed much lower amounts
of fibrinogen than one could expect from DVB-ST poly-
meric particles with the above specific surface area and a








Figure 4 Fibrinogen concentration in blood plasma (M ± SD; n = 3). It
particle-free 5% PVA, particle-free 3% agarose, PVA, and agarose composite
percolated through the pumping system without monoliths. Asterisk signifTable 1). This could be a consequence of low accessibility
of pores or, possibly, shielding of the bead surface by micro-
scopic fragments of cryogelated PVA or agarose. Fibrinogen
adsorption is known to mediate adhesion of platelets, the
phenomenon involved in the formation of thrombus
(Pulanic and Rudan 2005). The insignificant fibrinogen ad-
sorption on the composite cryogel monoliths can indicate
low thrombogenicity of the materials, though this requires
for a more detailed investigation of the blood coagulation
system brought into contact with the composites.1 1.5 2 2.5
Fibrinogen, mg/ml
is percolated through the different types of cryogel monoliths:
s, with embedded (DVB-ST) polymeric particles. The control is plasma
ies that p ≥ 0.05 in comparison with the native plasma.
Table 1 Characteristics of DVB-ST particles
Characteristic Value
Particle diameter (dp) 75 μm
Specific surface area (SBET) 641 m
2/g
Volume of micropores (Vmicro) 0.27 cm
3/g
Volume of mesopores (Vmeso) 0.88 cm
3/g
Volume of macropores (Vmacro) 0.22 cm
3/g
Average pore diameter (dpore) 7.7 nm
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Determination of C5a is one of the methods for the estima-
tion of complement system activation that resulted from
the contact of blood with artificial materials (ENSAI 2009).
C5a anaphylatoxin, formed as a part of the sequential cas-
cade of complement activation pathways, is known as a po-
tent pro-inflammatory agent, which takes part in leucocyte
activation, cytokine production, release of histamine etc.
(Sarma and Ward 2010). In the present study, the time-
dependent generation of C5a in the human blood se-
rum during its contact with particle-free or composite
monoliths has been examined. The concentration of C5a
in the serum incubated with slices of particle-free PVA and
agarose cryogels increased with time and, at the final point
(30 min), was 1.5 to 2 times higher than the initial value
(Figure 5a,b). These data demonstrated that both macro-
porous gels of agarose and PVA activated the complement
system in the human serum, which is in agreement with
earlier reported data (Lyle et al. 2010; Black and Sefton
2000; Arima et al. 2009) where the complement activation
through the alternative pathway by such polymers as agar-
ose (Lyle et al. 2010) and PVA (Black and Sefton 2000)
hydrogels has been shown. In those experiments, the con-
centrations of the Bb fragment and the soluble form of the
terminal membrane attack complex SC5b-9 were mea-
sured during the contact of hydrogels with blood serum
(Black and Sefton 2000). It is relevant to note that hydro-
phobic polymers such as polyethylene or polydimethylsi-
loxane brought into contact with serum caused a much
weaker activation of the complement compared with that
in hydrophilic polymers such as PVA or cellulose. Hea-
vily hydroxylated chains of these polymers are believed to
trigger the alternative pathway. In our experiments, com-
plement activation due to contact of serum with the com-
posite monoliths seemed to be relatively weak because the
positive control serum containing zymosan A exhibited a
much higher 11-fold increase in the concentration of C5a,
already after 10 min of incubation (Figure 5c).
There was no statistically valid difference between the
time dependent generation of C5a fragment in the serum
contacting the particle-free cryogels and the composites
(Figure 5a,b). A slight decrease in C5a concentration, ob-
served for both composites after 30 min of the contact,can be explained by adsorption of the C5a fragment on
the embedded DVB-ST polymeric particles. It seems like
the observed activation of the complement was mainly
due to the interaction of its components with the hydro-
philic PVA and agarose.
Conclusions
Macroporous monolithic composites based on cryo-
gelated PVA and agarose with embedded DVB-ST mi-
croparticles were prepared. The composites were densely
loaded with homogeneously distributed microparticles
and exhibited multiple interconnected pores with the
size of 4 to 180 μm. The porous structure allowed for
a facile percolation of blood plasma through the mono-
liths. The percolation did not influence fibrinogen con-
centration in the plasma, which indicated the absence of
any significant effect of the materials on the blood co-
agulation system. The contact of both particle-free and
composite monoliths with blood serum caused a slight
increase in the C5a concentration in the serum, which
was mainly due to the interaction of complement com-
ponents with cryogelated PVA and agarose. Embedment
of DVB-ST polymeric microparticles into the cryogel
monoliths may be advised for the further investigation
of these composites as a promising substance for the
synthesis of blood compatible materials.
Methods
Materials
Poly(vinyl alcohol) with an average molecular weight of
1.3 × 105 g/mol (Mowiol 18–88) was purchased from
Clariant GmbH (Frankfurt-on-Main, Germany). Agarose
(electrophoretic grade) was from Fluka (Buchs, Belgium).
DVB-ST polymeric particles (dp = 75 μm) were produced
by Polymerics GmbH (Berlin, Germany); their characteris-
tics are listed in Table 1. Glutaraldehyde (GA) (50% aque-
ous solution), zymosan A from Saccharomyces cerevisiae,
and other chemicals were obtained from Sigma-Aldrich
(St. Louis, MO, USA) or Merck (Darmstadt, Germany).
The commercially available ELISA kits from GENTAUR
(Kampenhout, Belgium) and CUSABIO (Wuhan, China)
were used for immunoassays of fibrinogen and C5a frag-
ment of complement in the blood plasma and serum,
respectively.
Methods
Preparation of cryogel monoliths
Cryogel-based monoliths were prepared in plastic syringes
according to the earlier reported technique (Plieva et al.
2006). In brief, PVA-based monoliths (3.2 cm in length
and 0.9 cm in diameter) were prepared from pre-cooled
5% PVA aqueous solution adjusted to pH 1.0 to 1.2 with 1
M HCl by cryogelation in an air bath cryostat (Arctest,
































































































Figure 5 Generation of C5a fragment in the human serum (M ± SD; n = 3). This took place after incubation with four different types of
cryogels: (a) slices of particle-free 5% PVA cryogel and PVA composite embedded with DVB-ST polymeric particles, (b) slices of particle-free 3%
agarose and agarose composite with embedded the DVB-ST polymeric particles, and (c) positive control (zymosan A, 4 mg/mL in serum). Asterisk
signifies that p ≤ 0.05 in comparison with the positive control.
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of NaBH4 was circulated through the columns by peri-
staltic pumping for the blocking of residual aldehyde
groups. The monoliths treated in that way were washed
with distilled water to neutralize pH, placed into 30%
v/v aqueous ethanol solution, and stored in a fridge at
+4°C.
Agarose-based cryogel monoliths were prepared from
3% agarose solution, adjusted to pH 12 with 5 M NaOH.The alkaline agarose solution pre-warmed in a water bath
at 60°C was placed into a liquid bath cryostat (Lauda,
Germany) at −32°C for 30 min for fast freezing and then
kept in the air bath cryostat at −12°C overnight. After
defrosting, all monoliths were washed with distilled water
to neutralize pH, placed into 30% ethanol solution, and
stored in a fridge at 4°C. Before the contact with blood
serum or blood plasma, the cryogel monoliths were
washed with distilled water and PBS (pH 7.4).
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ST polymeric particles were washed with 2-propanol,
distilled water, suspended in 5% w/v PVA or 3% w/v
agarose solutions, and rinsed with the same solutions.
The suspensions were adjusted to 250 mg/mL concen-
tration of DVB-ST particles in the polymer solutions,
which were put through cryogelation as described above.
Scanning electron microscopy examination
The monoliths have been examined under a scanning
electron microscope (JEOL JSM-5600LV, JEOL Ltd.,
Akishima, Tokyo, Japan). In order to prepare the sam-
ples for SEM, the top and bottom of each cryogel mono-
lith were cut off to get 4-mm-thick slices, which were
further incubated in 2.5% GA solution in 0.12 M sodium
phosphate buffer (pH 7.2) overnight. The samples were
dehydrated by soaking in aqueous ethanol of increasing
concentration (from 0% to 99.5% v/v), critical point
dried, and coated with gold/palladium (40:60).
Preparation of blood plasma and serum
Blood samples were taken from two voluntary healthy
donors into special plastic tubes to obtain the blood
serum or plasma (1 mL of 0.1 M sodium citrate to 9 mL
of blood). Tubes with the blood without anticoagulant
were immediately placed in a water bath at 37°C for clot
formation. Afterwards, all test tubes were centrifuged for
10 min at 5,000 rpm; serum and/or plasma were aspi-
rated, pooled into the plastic Falcon tubes, and placed in
a fridge at 4°C.
Percolation of blood plasma through the monoliths and
fibrinogen assay
Fibrinogen concentration in blood plasma was measured
before and after its circulation through the cryogel mono-
liths. Plasma (3.6 mL) was circulated through each of the
tested cryogel monoliths (0.9 cm × 3.2 cm) by peristaltic
pumping (WATSON MARLOW 101 U, Sweden) at 0.3
mL/min flow rate for 30 min. Instruction from the com-
mercially available column for extracorporeal blood purifi-
cation TORAYMYXIN PMX-20R (Toray Industries,
Tokyo, Japan) has been used for calculations of monolith
parameters, time of circulation and volume of plasma,
passing through (Toray Industries 2007). Control plasma
was passed through the empty syringe. Having been
passed through monoliths, the plasma samples were
stored at −20°C and assayed after defrosting according to
the manual for the ELISA kit.
Contact of blood serum with monoliths and C5a assay
Monoliths sliced into 3-mm-thick disks were incubated
in the blood serum (1 mL) for 0, 10, 20, and 30 min (37°C,
water bath). Having been incubated with monoliths,
serum was frozen, stored at −20°C, and assayed afterdefrosting according to the manual of the ELISA kit.
Zymosan A prepared as described earlier (Craddock et al.
1977) was used at a concentration of 4 mg/mL in the
serum as a positive control for the complement system ac-
tivation. According to the data presented in the literature,
the concentration of zymosan required for complement
activation in vitro is in the range of 1.0 to 5.0 mg/mL
(Craddock et al. 1977; Yuanyuan et al. 2001; Fehra and
Jacob 1977).
Statistical analysis
All calculations and construction of calibration curves
were performed using the Origin (Microcal Software
Inc., Northampton, MA, USA) and Excel (Microsoft
Corporation, Redmond, WA, USA) programs. Significant
difference between each two different groups of data was
examined using the Student's t test.
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